ArticleCureus2026
Intravenous Prostaglandin F2alpha for the Induction of Labor at a Japanese Perinatal Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo examine the effect and risks of using intravenous prostaglandin F2alpha, we retrospectively reviewed our cases using intravenous prostaglandin F2alpha for labor induction.
methodsWe reviewed the obstetric records of all nulliparous singleton deliveries at ≥ 22 weeks of gestation from 2004 to 2008 (n = 6,596).
resultsWe used intravenous prostaglandin F2alpha to induce labor in 158 nulliparous pregnant women (2.4%) at 39.2 ± 1.4 weeks of gestation under the protocol based on the Japanese clinical practice guidelines. Of these, 64 cases (40.5%) resulted in vaginal delivery, and 44 (27.8%) underwent cesarean delivery during the procedure of intravenous administration of prostaglandin F2alpha. Only one case (0.6%) developed uterine hyperstimulation requiring prompt delivery under the use of prostaglandin F2alpha. There were no cases of serious complications such as fetal death, uterine rupture, or other maternal complications.
conclusionIntravenous prostaglandin F2alpha used under the strict protocols seems to be one of the methods that can safely induce labor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.